MARATTO

article · INTERNATIONAL JOURNAL OF CLINICAL SCIENCE AND MEDICAL RESEARCH

Diagnosis and Prognosis Utility of microRNA-205 Expression in Prostate Carcinogenesis: Meta-Analysis and Bioinformatics Study

20241 citationOpen accessMohammed V University

Abstract

Background: Prostate cancer (PCa) is a common disease that affects millions of men worldwide. Precise and non-invasive markers for diagnosing and prognosing PCa are vital to enhance patient management. MicroRNAs have been proposed as non-invasive biomarkers. We performed a meta-analysis and a bioinformatics study of miR-205 to give a full assessment of its diagnostic and prognostic relevance. Materials and methods: We searched all published papers on miR-205 expression in PCa up to April 30, 2023 using PubMed, sciencedirect, Google Scolar, Web of Science. We used RevMan software to Meta-analyze the included literature. A bioinformatics investigation of genes and pathways that may be targets of the mature miR-205-5p impact was also performed. Results: The pooled standardized mean difference of miR-205 differential expression in PCa compared to normal tissue, in primary and progressed cancer and hazard ratio were -1.58; p˂0.001, -0.23; p=0.06 and 2.61; p=0.002 respectively. Bioinformatics analysis revealed that miR-205-5p may regulate YAP1 and the Hippo signaling pathway. Conclusion: The current study found that miRNA-205 is downregulated in PCa and have a significant prognostic value. MiRNA-205 may have a role in prostate carcinogenesis via regulating YAP1 through the Hippo signaling pathway.

Research topics

  • Hippo pathway signaling and YAP/TAZ

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.55677/ijcsmr/v4i3-01/2024

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.